VIR vs. VRNA, GRFS, TGTX, KRYS, SWTX, BHVN, RXRX, PTCT, OGN, and RARE
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Verona Pharma (VRNA), Grifols (GRFS), TG Therapeutics (TGTX), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.
Vir Biotechnology vs.
Vir Biotechnology (NASDAQ:VIR) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
In the previous week, Vir Biotechnology had 1 more articles in the media than Verona Pharma. MarketBeat recorded 7 mentions for Vir Biotechnology and 6 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.76 beat Vir Biotechnology's score of 0.46 indicating that Verona Pharma is being referred to more favorably in the news media.
65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by insiders. Comparatively, 4.8% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Verona Pharma has lower revenue, but higher earnings than Vir Biotechnology. Verona Pharma is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Verona Pharma has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat Verona Pharma's return on equity.
Vir Biotechnology has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.
Vir Biotechnology presently has a consensus price target of $34.83, suggesting a potential upside of 263.98%. Verona Pharma has a consensus price target of $57.14, suggesting a potential downside of 15.92%. Given Vir Biotechnology's higher probable upside, research analysts plainly believe Vir Biotechnology is more favorable than Verona Pharma.
Verona Pharma received 276 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 80.84% of users gave Verona Pharma an outperform vote while only 54.64% of users gave Vir Biotechnology an outperform vote.
Summary
Verona Pharma beats Vir Biotechnology on 11 of the 19 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 2/22/2025 by MarketBeat.com Staff
Free VIR Stock Alerts